Rivastigmine transdermal patch: Role in the management of Alzheimer's disease

Consultant Pharmacist

Volumn 23, Issue 8, 2008, Pages 598-609

  Guay, David R P ^a,b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b HEALTHPARTNERS INSTITUTE   (United States)

Author keywords

Acetylcholinesterase; Alzheimer's disease; Butyrylcholinesterase; Dementia; Parkinsonian dementia; Rivastigmine; Transdermal

Indexed keywords

CARBAMIC ACID DERIVATIVE; CHOLINESTERASE INHIBITOR; RIVASTIGMINE;

ALZHEIMER DISEASE; CHEMISTRY; HUMAN; INTRADERMAL DRUG ADMINISTRATION; PRACTICE GUIDELINE; REVIEW;

ADMINISTRATION, CUTANEOUS; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; HUMANS; PHENYLCARBAMATES; PRACTICE GUIDELINES AS TOPIC;

EID: 58149339689     PISSN: 08885109     EISSN: None     Source Type: Journal    
DOI: 10.4140/TCP.n.2008.598     Document Type: Review

References (20)

1. Rubin CD.The primary care of Alzheimer's disease.Am J Med Sci 2006;332:314-33.
2. Lobo A, Launer LJ, Fratiglioni L et al. Prevalence of dementia and major subtypes in Europe: a collaborative study of population-based cohorts. Neurology 2000;54 Suppl 5:4-9.
3. Raina P, Santaguida P, Ismaila A et al. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann Intern Med 2008;148:379-97. (Pubitemid 351665469)
4. Cummings J, Lefevre G, Small G et al. Pharmacokinetic rationale for the rivastigmine patch. Neurology 2007;69 4 Suppl 1:10-3.
5. Small G, Dubois B. A review of compliance to treatment in Alzeimer's disease: potential benefits of aTD patch. Curr Med Res Opin 2007;23: 2705-13. (Pubitemid 350146408)
6. Rivastigmine tartrate capsules and oral solution (Exelon) product labeling. East Hanover, NJ: Novartis Pharmaceuticals Corporation; July 2007.
7. Feldman HH, Lane R, Study 304 Group. Rivastigmine: a placebo-controlled trial of twice daily and three times daily regimens in patients with Alzheimer's disease. J Neurol Neurosurg Psychiatry 2007;78:1056-63.
8. Jann MW. Rivastigmine, a new-generation cholinesterase inhibitor for the treatment of Alzeimer's disease. Pharmacotherapy 2000;20:1-12. (Pubitemid 30036098)
9. OertelW, Ross JS, Eggert K et al. Rationale forTD drug administration in Alzheimer's disease. Neurology 2007;69 Suppl 1:4-9.
10. Lefevre G, Sedek G, Jhee SS et al. Pharmacokinetics and pharmacodynamics of the novel daily rivastigmineTD patch compared with twice-daily capsules in Alzheimer's disease patients. Clin PharmacolTher 2008;83:106-14.
11. Lefevre G, Sedek G, Huang H-LA et al. Pharmacokinetics of rivastigmineTD patch formulation in healthy volunteers: relative effects of body site application. J Clin Pharmacol 2007;47:471-8. (Pubitemid 46465956)
12. Winblad B, Cummings J, Andreasen N et al.A six-month double-blind, randomized, placebo-controlled study of aTD patch in Alzheimer's disease- rivastigmine patch versus capsule. Int J Geriatr Psychiatr 2007;22:456-67. (Pubitemid 46831690)
13. Muhlak S, Przuntek H, Muller T. Transdermal rivastigmine treatment does not worsen impaired performance of complex motions in patients with Alzheimer's disease. Pharmacopsychiatry 2006;39:16-9. (Pubitemid 43235445)
14. Tse FLS, Laplanche R. Absorption, metabolism, and disposition of [14C] SDZ ENA 713, an acetylcholinesterase inhibitor, in minipigs following oral, intravenous, and dermal administration. Pharm Res 1998;15:1614-20.
15. Exelon 4.6 and 9.5 mg/24 hoursTD patch: summary of product characteristics. Horsham, UK: Novartis Europharm Ltd; 2007.
16. Rivastigmine tartrateTD system (Exelon) product labeling. East Hanover, NJ: Novartis Pharmaceuticals Corporation; July 2007.
17. Winblad B, Kawata AK, Beusterien KM et al. Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer's disease. Int J Geriatr Psychiatr 2007;22:485-91. (Pubitemid 46831693)
18. Donepezil hydrochloride tablets and oral disintegrating tablets (Aricept®, Aricept® ODT) product labeling. Woodcliff Lake, NJ: Eisai Inc; November 2006.
19. Galantamine hydrobromide tablets, oral solution, and extended-release capsules (Razadyne® , Razadyne® ER) product labeling.Titusville, NJ: Ortho-McNeil Neurologics;April 2007.
20. QaseemA, SnowV, Cross JT Jr. et al. Current pharmacologic treatment of dementia: a clinical practice guideline from the American College of Physicians and the American Academy of Family Practitioners.Ann Intern Med 2008;148:370-8.